ZIVO Bioscience (NASDAQ:ZIVO) (NASDAQ: ZIVO) is a clinical‐stage biotechnology company dedicated to the development of next‐generation vaccine adjuvants and immunotherapies. The company’s proprietary ZIVO adjuvant platform is designed to activate innate immunity, providing broad‐spectrum protection and enhancing the efficacy of conventional vaccines. By targeting pattern recognition receptors and stimulating dendritic cells, ZIVO aims to deliver rapid, durable immune responses against emerging infectious diseases and cancer.
The company’s lead product candidates leverage saponin‐based and nanoparticle formulations to facilitate targeted delivery of immune stimulants. ZIVO’s pipeline includes both prophylactic and therapeutic candidates for viral pathogens such as influenza and coronaviruses, as well as oncology indications where robust activation of the innate immune system may improve antitumor efficacy. Preclinical studies have demonstrated favorable safety profiles and enhanced antigen presentation, positioning ZIVO’s adjuvants for potential use in combination with mRNA, subunit, and inactivated vaccines.
Founded in 2016 and headquartered in Austin, Texas, ZIVO Bioscience has built a multidisciplinary team of immunologists, formulation scientists, and clinical development experts. The company operates research laboratories in the United States and collaborates with leading academic institutions and contract research organizations to advance its portfolio. Through strategic partnerships, ZIVO is advancing its technology toward Investigational New Drug (IND) applications and exploring opportunities in both human and veterinary health markets.
Under the leadership of Chief Executive Officer Michael L. McHugh and Chief Scientific Officer Dr. Jennifer L. Anders, ZIVO Bioscience combines deep industry experience with a focus on rapid innovation. The management team’s collective background spans major pharmaceutical companies, biotech startups, and regulatory agencies. Together, they are working to position ZIVO as a potential leader in the emerging field of innate immune modulators, aiming to address urgent public health needs and enhance global vaccine preparedness.
